GLA
CERE

Great Lakes Advisors’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Great Lakes Advisors’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-172,337
Closed -$7.05M – 911
2024
Q2 		$7.05M Sell
172,337
-160,984
-48% -$6.7M 0.06% 244
2024
Q1 		$14.1M Buy
+333,321
New +$14M 0.12% 168

Other funds holding CERE

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $8.74B AUM 14.62% 1-Year Est. Return

Great Lakes Advisors's CERE Position: Q3 2024 in Review

Great Lakes Advisors sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2024, closing a stake of 172,337 shares — an estimated $7.05M sold.

Great Lakes Advisors first reported a position in CERE in Q1 2024 and held it in 2 quarters. The position peaked at $14.1M in Q1 2024. 2 funds tracked by Wall St. Rank hold CERE as of Q3 2024.

  • Great Lakes Advisors reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
  • Great Lakes Advisors sold 172,337 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2024, an estimated $7.05M.
  • Great Lakes Advisors first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2024 and held it in 2 quarters.
  • Great Lakes Advisors's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $14.1M in Q1 2024.
  • 2 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2024.

Based on Great Lakes Advisors's 13F filing for Q3 2024, filed 4 Nov 2024.